Expansion into new therapies Immunocore is developing ImmTAX, a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases. This innovative therapy approach presents an opportunity for collaboration or licensing agreements.
Recent IPO Immunocore recently went public, indicating financial stability and growth potential. This milestone signifies a potential interest from investors and partners looking to capitalize on the company's success.
New client acquisition Immunocore's partnership with Genedata AG for scaling up the discovery of TCR therapeutics showcases a focus on expansion and innovation. This presents an opportunity for service providers and technology vendors to offer their solutions.
Leadership transition The upcoming departure of Immunocore's Chief Financial Officer and Head of Strategy presents a chance for financial consulting firms or executive recruitment agencies to engage with the company and provide their expertise in filling key roles.
Pipeline development Immunocore's efforts in developing a pipeline of treatments for various diseases indicate a future need for partners or collaborators in clinical trials and commercialization. This opens doors for pharmaceutical companies or CROs to explore potential collaborations.
565
$100M$1B
296$50M$100M
108$10M$50M
106$10M$50M
201$50M$100MImmunocore uses 8 technology products and services including Linkedin Insight Tag, Skillsoft, Microsoft Word, and more. Explore Immunocore's tech stack below.
| Immunocore Email Formats | Percentage |
| First.Last@immunocore.com | 94% |
| F.Last@immunocore.com | 3% |
| First@immunocore.com | 2% |
| First.Middle@immunocore.com | 1% |
Biotechnology ResearchOxfordshire, United Kingdom501-1000 Employees
Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr
Company Overview
Funding & FinancialsImmunocore has raised a total of $350M of funding over 8 rounds. Their latest funding round was raised on Jan 30, 2024 in the amount of $350M.
Immunocore's revenue is in the range of $50M$100M
Funding & FinancialsImmunocore has raised a total of $350M of funding over 8 rounds. Their latest funding round was raised on Jan 30, 2024 in the amount of $350M.
Immunocore's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com